John D. Quisel Sells 13,012 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CEO John D. Quisel sold 13,012 shares of the business's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $61.95, for a total value of $806,093.40. Following the sale, the chief executive officer now owns 72,065 shares in the company, valued at $4,464,426.75. The trade was a 15.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Disc Medicine Stock Down 1.5 %

Shares of IRON traded down $0.95 during mid-day trading on Thursday, reaching $62.45. The company had a trading volume of 257,727 shares, compared to its average volume of 341,703. The stock has a 50 day moving average of $61.20 and a two-hundred day moving average of $51.99. The stock has a market capitalization of $1.86 billion, a P/E ratio of -15.69 and a beta of 0.76. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping analysts' consensus estimates of ($1.04) by $0.15. On average, sell-side analysts expect that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank grew its position in shares of Disc Medicine by 76.9% during the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after acquiring an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock valued at $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine in the second quarter valued at approximately $129,000. Quest Partners LLC acquired a new stake in shares of Disc Medicine in the third quarter valued at about $131,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Disc Medicine in the third quarter valued at about $146,000. Hedge funds and other institutional investors own 83.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. HC Wainwright reiterated a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a research note on Monday, December 9th. Wedbush reissued an "outperform" rating and issued a $83.00 target price on shares of Disc Medicine in a research report on Monday, December 9th. Morgan Stanley raised Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price target for the company in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group assumed coverage on Disc Medicine in a report on Wednesday, October 23rd. They issued a "buy" rating and a $89.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Disc Medicine currently has a consensus rating of "Buy" and a consensus price target of $87.50.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.